A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.

Trial Profile

A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms HERO
  • Most Recent Events

    • 04 May 2012 Additional lead trial investigator (D. Bredenbroker) identified as reported by ClinicalTrials.gov.
    • 04 May 2012 Company added to the associations field as reported by ClinicalTrials.gov record.
    • 25 Jan 2012 Additional trial identifier (NCT00108823) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top